With trials on a pandemic pause, Winston & Strawn's gross revenue declined by roughly 3% to $981.2 million last year. But profits were bolstered by reduced expenses, said firm chairman Tom Fitzgerald, and profits per equity partner increased by 4.6%, to $2.42 million.